428 related articles for article (PubMed ID: 9179871)
21. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
22. Chimaeric VIP2/PACAP receptors reveal that agonist pharmacology but not signal transduction is determined by extracellular domain 1.
Lutz EM; MacKenzie CJ; Morrow J; Mitchell R; Bennie J; Carroll S; Clark E; Harmar AJ
Ann N Y Acad Sci; 1996 Dec; 805():574-8. PubMed ID: 8993442
[No Abstract] [Full Text] [Related]
23. Pharmacological evidence for both neuronal and smooth muscular PAC1 receptors and a VIP-specific receptor in rat colon.
Ekblad E
Regul Pept; 1999 Dec; 85(2-3):87-92. PubMed ID: 10651061
[TBL] [Abstract][Full Text] [Related]
24. PACAP and VIP stimulate Ca2+ oscillations in rat gonadotrophs through the PACAP/VIP type 1 receptor (PVR1) linked to a pertussis toxin-insensitive G-protein and the activation of phospholipase C-beta.
Hezareh M; Schlegel W; Rawlings SR
J Neuroendocrinol; 1996 May; 8(5):367-74. PubMed ID: 8736436
[TBL] [Abstract][Full Text] [Related]
25. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
[TBL] [Abstract][Full Text] [Related]
26. Role of PAC(1) receptor in adrenal catecholamine secretion induced by PACAP and VIP in vivo.
Lamouche S; Yamaguchi N
Am J Physiol Regul Integr Comp Physiol; 2001 Feb; 280(2):R510-8. PubMed ID: 11208582
[TBL] [Abstract][Full Text] [Related]
27. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
28. VIP and PACAP receptor-mediated actions on cell proliferation and survival.
Waschek JA
Ann N Y Acad Sci; 1996 Dec; 805():290-300; discussion 300-1. PubMed ID: 8993411
[No Abstract] [Full Text] [Related]
29. Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats.
Läuffer JM; Modlin IM; Hinoue T; Kidd M; Zhang T; Schmid SW; Tang LH
Gastroenterology; 1999 Mar; 116(3):623-35. PubMed ID: 10029621
[TBL] [Abstract][Full Text] [Related]
30. Pituitary adenylate cyclase-activating peptide and vasoactive intestinal peptide receptor expression in immortalized LHRH neurons.
Olcese J; McArdle CA; Middendorff R; Greenland K
J Neuroendocrinol; 1997 Dec; 9(12):937-43. PubMed ID: 9468019
[TBL] [Abstract][Full Text] [Related]
31. A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide.
Straub SG; Sharp GW
J Biol Chem; 1996 Jan; 271(3):1660-8. PubMed ID: 8576167
[TBL] [Abstract][Full Text] [Related]
32. Multiple signal pathways coupling VIP and PACAP receptors to calcium channels in hamster submandibular ganglion neurons.
Kamaishi H; Endoh T; Suzuki T
Auton Neurosci; 2004 Mar; 111(1):15-26. PubMed ID: 15109935
[TBL] [Abstract][Full Text] [Related]
33. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
34. Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor.
Tachibana T; Saito ES; Takahashi H; Saito S; Tomonaga S; Boswell T; Furuse M
Regul Pept; 2004 Aug; 120(1-3):99-105. PubMed ID: 15177926
[TBL] [Abstract][Full Text] [Related]
35. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.
Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
Regul Pept; 1996 Apr; 62(2-3):125-30. PubMed ID: 8795075
[TBL] [Abstract][Full Text] [Related]
36. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide activate hyperpolarization-activated cationic current and depolarize thalamocortical neurons in vitro.
Sun QQ; Prince DA; Huguenard JR
J Neurosci; 2003 Apr; 23(7):2751-8. PubMed ID: 12684461
[TBL] [Abstract][Full Text] [Related]
37. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
[TBL] [Abstract][Full Text] [Related]
38. Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms.
Braas KM; May V
Ann N Y Acad Sci; 1996 Dec; 805():204-16; discussion 217-8. PubMed ID: 8993404
[TBL] [Abstract][Full Text] [Related]
39. Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and their receptors in the human adrenal gland.
Mazzocchi G; Malendowicz LK; Rebuffat P; Gottardo L; Nussdorfer GG
J Clin Endocrinol Metab; 2002 Jun; 87(6):2575-80. PubMed ID: 12050216
[TBL] [Abstract][Full Text] [Related]
40. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
